• Open Access

Intravenous Administration of Docetaxel to Cats with Cancer

Authors


  • Presented in abstract form at the 30th Annual Conference of the Veterinary Cancer Society, San Diego, CA, October 2010.

Corresponding author: David M. Vail, Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53706; e-mail: vaild@svm.vetmed.wisc.edu.

Abstract

Background: The safety of IV administration of docetaxel to cats with cancer has not been reported.

Objectives: Document adverse effects of IV administration of docetaxel to cats.

Animals: Twenty-one client-owned cats with any confirmed malignancy.

Methods: Cats received up to 5 docetaxel treatments, administered IV every 3 weeks. The initial dosage was 1.0 mg/kg, and dosages were increased by increments of 0.25 mg/kg in cohorts of 3 cats. Adverse events were determined by a CBC at days 7 and 21, serum chemistry and urine specific gravity at day 21, and medical histories provided by the owners.

Results: Cats received docetaxel dosages ranging from 1.0 to 2.5 mg/kg, for a median of 2 treatments. Dose-limiting toxicoses included fever, neutropenia, and vomiting, seen in 2 of the 4 cats treated at 2.5 mg/kg. Hypersensitivity reactions were infrequent (4 of the 21 cats) and mild. The maximum tolerated dosage was 2.25 mg/kg.

Conclusions and Clinical Importance: Docetaxel can be administered IV to cats with a low incidence of adverse effects.

Ancillary